Notebookcheck Logo
, , , , , ,
search relation.
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
 

EYVA: World's first non-invasive glucose monitor could cost the equivalent of just over US$200 - no blood required but it's not medical grade

The EYVA non-invasive glucose and healthtech monitor is being manufactured in India. (Image source: EYVA - edited)
The EYVA non-invasive glucose and healthtech monitor is being manufactured in India. (Image source: EYVA - edited)
The EYVA device is, according to the startup behind it, not only the world’s first non-invasive glucose monitor but also the world’s first healthtech gadget. The EYVA can check the user’s blood sugar levels and also measure things such as temperature and SpO2. The non-invasive gadget has been designed by an Indian startup called BlueSemi.

Progress with the EYVA healthtech gadget seems to be going ahead after BlueSemi exhibited the device at the recent CES show. Billed as the world’s first non-invasive glucose monitor, EYVA is actually capable of taking six biometric readings within just 60 seconds: blood glucose, temperature, ECG, heart rate, SpO2 for blood oxygen, and blood pressure. The gadget was created by BlueSemi, which is a healthtech startup based in Hyderabad, India.

While visitors to CES who tried out the EYVA device seemed pretty convinced by the gadget, it appears it is being targeted as a companion monitor rather than as a complete replacement to a medically proven method of blood sugar monitoring. Users press their fingers onto the device, which seems to have been designed with both form and substance in mind, and then the data is sent to a bespoke app on a smartphone that displays the vital information – as the EYVA itself does not have its own display.

According to reports, the EYVA non-invasive glucose monitor offers “90 per cent accuracy” and the CEO of BlueSemi, Sunil Maddikatla, has stated that the gadget is not of a medical-grade standard. However, by not pursuing a medical-grade level, it means the EYVA is more likely to be certified for sale outside of its domestic market of India, with future US and Europe availability seemingly on the cards.

By using “sensor fusion” involving nine sensors and artificial intelligence, the EYVA device can measure blood glucose levels to give the user an idea of the state of their health. Approximately 77 million people have diabetes in India and this figure could hit 134 million by 2045, so it makes sense that an Indian startup could lead the charge in non-invasive glucose monitor development. The EYVA is expected to cost ₹15,490 (about US$208) per unit with limited shipments supposedly starting in March of this year.

Buy Contour Next blood glucose strips on Amazon

EYVA glucose monitor. (Image source: BlueSemi via YouTube)
EYVA glucose monitor
EYVA glucose monitor. (Image source: BlueSemi via The Indian Express)
EYVA glucose monitor
EYVA glucose monitor. (Image source: BlueSemi via The Indian Express)
EYVA glucose monitor
EYVA glucose monitor. (Image source: BlueSemi via The Indian Express)
EYVA glucose monitor

Source(s)

static version load dynamic
Loading Comments
Comment on this article
Daniel R Deakin
Daniel R Deakin - Managing Editor News - 2697 articles published on Notebookcheck since 2012
My interest in technology began after I was presented with an Atari 800XL home computer in the mid-1980s. I especially enjoy writing about technological advances, compelling rumors, and intriguing tech-related leaks. I have a degree in International Relations and Strategic Studies and count my family, reading, writing, and travel as the main passions of my life. I have been with Notebookcheck since 2012.
Please share our article, every link counts!
> Notebook / Laptop Reviews and News > News > News Archive > Newsarchive 2022 01 > EYVA: World's first non-invasive glucose monitor could cost the equivalent of just over US$200 - no blood required but it's not medical grade
Daniel R Deakin, 2022-01-20 (Update: 2022-01-20)